PortalPublikationenImproved outcome of patients with graft-versus-host disease ...

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study

Standard

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. / Greinix, Hildegard T; Eikema, Dirk-Jan; Koster, Linda; Penack, Olaf; Yakoub-Agha, Ibrahim; Montoto, Silvia; Chabannon, Christian; Styczynski, Jan; Nagler, Arnon; Robin, Marie; Robinson, Stephen; Chalandon, Yves; Mikulska, Malgorzata; Schönland, Stefan; Peric, Zinaida; Ruggeri, Annalisa; Lanza, Francesco; De Wreede, Liesbeth C; Mohty, Mohamad; Basak, Grzegorz W; Kröger, Nicolaus.

in: HAEMATOLOGICA, Jahrgang 107, Nr. 5, 01.05.2022, S. 1054-1063.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Greinix, HT, Eikema, D-J, Koster, L, Penack, O, Yakoub-Agha, I, Montoto, S, Chabannon, C, Styczynski, J, Nagler, A, Robin, M, Robinson, S, Chalandon, Y, Mikulska, M, Schönland, S, Peric, Z, Ruggeri, A, Lanza, F, De Wreede, LC, Mohty, M, Basak, GW & Kröger, N 2022, 'Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study', HAEMATOLOGICA, Jg. 107, Nr. 5, S. 1054-1063. https://doi.org/10.3324/haematol.2020.265769

APA

Greinix, H. T., Eikema, D-J., Koster, L., Penack, O., Yakoub-Agha, I., Montoto, S., Chabannon, C., Styczynski, J., Nagler, A., Robin, M., Robinson, S., Chalandon, Y., Mikulska, M., Schönland, S., Peric, Z., Ruggeri, A., Lanza, F., De Wreede, L. C., Mohty, M., ... Kröger, N. (2022). Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. HAEMATOLOGICA, 107(5), 1054-1063. https://doi.org/10.3324/haematol.2020.265769

Vancouver

Greinix HT, Eikema D-J, Koster L, Penack O, Yakoub-Agha I, Montoto S et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. HAEMATOLOGICA. 2022 Mai 1;107(5):1054-1063. https://doi.org/10.3324/haematol.2020.265769

Bibtex

@article{c18b0ced8f6f493e835f98ff91b33ddc,
title = "Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study",
abstract = "Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P<0.001). In multivariate analysis URD, not in complete remission (CR) at transplant or untreated, and female donor for male recipient were factors associated with increased risk whereas the use of ATG/alemtuzumab decreased aGvHD incidence. Median follow-up was 214, 169, 127, 81 and 30 months, respectively, for the periods analyzed. Three-year-survival after aGvHD grades II-IV increased significantly from 38% to 40%, 43%, 44%, and 45%, respectively. In multivariate analysis URD, not in CR at transplant, peripheral blood as stem cell source, female donor for male recipient, and the use of ATG/alemtuzumab were associated with increased mortality whereas reduced-intensity conditioning was linked to lower mortality. Mortality increased with increasing patient age but decreased in the recent cohorts. Our analysis demonstrates that aGvHD has decreased over recent decades and also that the survival rates of patients affected with aGvHD has improved.",
author = "Greinix, {Hildegard T} and Dirk-Jan Eikema and Linda Koster and Olaf Penack and Ibrahim Yakoub-Agha and Silvia Montoto and Christian Chabannon and Jan Styczynski and Arnon Nagler and Marie Robin and Stephen Robinson and Yves Chalandon and Malgorzata Mikulska and Stefan Sch{\"o}nland and Zinaida Peric and Annalisa Ruggeri and Francesco Lanza and {De Wreede}, {Liesbeth C} and Mohamad Mohty and Basak, {Grzegorz W} and Nicolaus Kr{\"o}ger",
year = "2022",
month = may,
day = "1",
doi = "10.3324/haematol.2020.265769",
language = "English",
volume = "107",
pages = "1054--1063",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "5",

}

RIS

TY - JOUR

T1 - Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study

AU - Greinix, Hildegard T

AU - Eikema, Dirk-Jan

AU - Koster, Linda

AU - Penack, Olaf

AU - Yakoub-Agha, Ibrahim

AU - Montoto, Silvia

AU - Chabannon, Christian

AU - Styczynski, Jan

AU - Nagler, Arnon

AU - Robin, Marie

AU - Robinson, Stephen

AU - Chalandon, Yves

AU - Mikulska, Malgorzata

AU - Schönland, Stefan

AU - Peric, Zinaida

AU - Ruggeri, Annalisa

AU - Lanza, Francesco

AU - De Wreede, Liesbeth C

AU - Mohty, Mohamad

AU - Basak, Grzegorz W

AU - Kröger, Nicolaus

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P<0.001). In multivariate analysis URD, not in complete remission (CR) at transplant or untreated, and female donor for male recipient were factors associated with increased risk whereas the use of ATG/alemtuzumab decreased aGvHD incidence. Median follow-up was 214, 169, 127, 81 and 30 months, respectively, for the periods analyzed. Three-year-survival after aGvHD grades II-IV increased significantly from 38% to 40%, 43%, 44%, and 45%, respectively. In multivariate analysis URD, not in CR at transplant, peripheral blood as stem cell source, female donor for male recipient, and the use of ATG/alemtuzumab were associated with increased mortality whereas reduced-intensity conditioning was linked to lower mortality. Mortality increased with increasing patient age but decreased in the recent cohorts. Our analysis demonstrates that aGvHD has decreased over recent decades and also that the survival rates of patients affected with aGvHD has improved.

AB - Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P<0.001). In multivariate analysis URD, not in complete remission (CR) at transplant or untreated, and female donor for male recipient were factors associated with increased risk whereas the use of ATG/alemtuzumab decreased aGvHD incidence. Median follow-up was 214, 169, 127, 81 and 30 months, respectively, for the periods analyzed. Three-year-survival after aGvHD grades II-IV increased significantly from 38% to 40%, 43%, 44%, and 45%, respectively. In multivariate analysis URD, not in CR at transplant, peripheral blood as stem cell source, female donor for male recipient, and the use of ATG/alemtuzumab were associated with increased mortality whereas reduced-intensity conditioning was linked to lower mortality. Mortality increased with increasing patient age but decreased in the recent cohorts. Our analysis demonstrates that aGvHD has decreased over recent decades and also that the survival rates of patients affected with aGvHD has improved.

U2 - 10.3324/haematol.2020.265769

DO - 10.3324/haematol.2020.265769

M3 - SCORING: Journal article

C2 - 34162176

VL - 107

SP - 1054

EP - 1063

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 5

ER -